Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares stood at 32.88 million during the last session, with the company’s beta value hitting 0.87. At the close of trading, the stock’s price was $5.40, to imply a decrease of -0.92% or -$0.05 in intraday trading. The RXRX share’s 52-week high remains $12.36, putting it -128.89% down since that peak but still an impressive 29.81% since price per share fell to its 52-week low of $3.79.
Analysts have given a consensus recommendation of Buy for Recursion Pharmaceuticals Inc (RXRX), translating to a mean rating of 2.43. Of 3 analyst(s) looking at the stock, 0 analyst(s) give RXRX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
After registering a -0.92% downside in the last session, Recursion Pharmaceuticals Inc (RXRX) has traded red over the past five days. The 5-day price performance for the stock is 9.98%, and 16.38% over 30 days. With these gigs, the year-to-date price performance is -20.12%.
The extremes give us $6 and $6 for target low and target high price respectively. As such, RXRX has been trading -11.11% off suggested target high and -11.11% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -35.28% for the past 5-year period. While 2025 is set for a 16.05% return in earnings, projections for the next 5 years are at 21.63% annually.
RXRX Dividends
Recursion Pharmaceuticals Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is BAILLIE GIFFORD & CO with 26.59 million shares, or about 10.9787% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $199.42 million.
